Chronic obstructive pulmonary disease, or COPD, is a condition that affects more than just longtime smokers. According to recent studies, women are disproportionately impacted, and exposure to poor air quality plays a significant role in its development.
COPD claims roughly 142,000 lives each year nationwide, affecting about 4% of all U.S. adults - or over 11 million people. While the condition is often associated with smoking, research has shown that non-smokers can also be at risk if they are exposed to poor air quality or occupational health hazards.
Symptoms of COPD include frequent coughing, wheezing sounds while breathing, shortness of breath during exercise, and chest tightness. Despite these warning signs, many cases remain undiagnosed, particularly in women. Research has shown that more women than men are diagnosed with COPD and die from the disease.
Women's smaller lungs and airways may contribute to their increased sensitivity to damage, making smoking more harmful for them. This is why many women with COPD have smoked less than men who develop the disease. Dr. Jamie Garfield, a pulmonologist at the Temple Lung Center, notes that "many diseases and conditions present differently in women than in men," and COPD is one of them.
Treatment options for COPD include medications such as inhalers to open airways or reduce inflammation, pulmonary rehabilitation programs that combine exercise, education, and breathing strategies, oxygen therapy, and surgical options like lung volume reduction procedures. The Temple Lung Center offers tailored treatment plans to each patient's needs and connects eligible patients with clinical trials testing the latest therapies.
However, the environment plays a significant role in COPD development. Philadelphia's air quality is worse than the national average, making it particularly concerning for residents. According to the American Lung Association's 2025 "State of the Air" report, Philadelphia County received an F grade for particle pollution, ranking among the worst in the country and third worst in the Mid-Atlantic.
Dr. Gerard Criner, director of the Temple Health Lung Center, emphasizes that air pollution is increasingly recognized as a driver of lung disease. Living in a city like Philadelphia, where air quality ranks below the national average, means the environment itself becomes a risk factor for COPD.
Despite these challenges, researchers at the Temple Lung Center are advancing treatment through research. The center operates one of the largest and most comprehensive COPD programs in the country, combining advanced clinical care with groundbreaking research. They have contributed to global standards for COPD management and run one of the highest-volume lung transplant programs in the United States.
Recent breakthroughs include participation in the BREATHE-3 clinical trial, which evaluates a new bronchoscopic device designed to relieve trapped air in the lungs and help patients breathe more easily. The Temple Lung Center enrolls hundreds of patients in clinical trials each year, offering access to treatments that are reshaping the future of care.
According to Dr. Criner, "the future of COPD care is about creating treatments that allow patients to live fuller lives." With new therapies and a growing understanding of how environment and gender play a role, there is growing hope for patients with COPD.
COPD claims roughly 142,000 lives each year nationwide, affecting about 4% of all U.S. adults - or over 11 million people. While the condition is often associated with smoking, research has shown that non-smokers can also be at risk if they are exposed to poor air quality or occupational health hazards.
Symptoms of COPD include frequent coughing, wheezing sounds while breathing, shortness of breath during exercise, and chest tightness. Despite these warning signs, many cases remain undiagnosed, particularly in women. Research has shown that more women than men are diagnosed with COPD and die from the disease.
Women's smaller lungs and airways may contribute to their increased sensitivity to damage, making smoking more harmful for them. This is why many women with COPD have smoked less than men who develop the disease. Dr. Jamie Garfield, a pulmonologist at the Temple Lung Center, notes that "many diseases and conditions present differently in women than in men," and COPD is one of them.
Treatment options for COPD include medications such as inhalers to open airways or reduce inflammation, pulmonary rehabilitation programs that combine exercise, education, and breathing strategies, oxygen therapy, and surgical options like lung volume reduction procedures. The Temple Lung Center offers tailored treatment plans to each patient's needs and connects eligible patients with clinical trials testing the latest therapies.
However, the environment plays a significant role in COPD development. Philadelphia's air quality is worse than the national average, making it particularly concerning for residents. According to the American Lung Association's 2025 "State of the Air" report, Philadelphia County received an F grade for particle pollution, ranking among the worst in the country and third worst in the Mid-Atlantic.
Dr. Gerard Criner, director of the Temple Health Lung Center, emphasizes that air pollution is increasingly recognized as a driver of lung disease. Living in a city like Philadelphia, where air quality ranks below the national average, means the environment itself becomes a risk factor for COPD.
Despite these challenges, researchers at the Temple Lung Center are advancing treatment through research. The center operates one of the largest and most comprehensive COPD programs in the country, combining advanced clinical care with groundbreaking research. They have contributed to global standards for COPD management and run one of the highest-volume lung transplant programs in the United States.
Recent breakthroughs include participation in the BREATHE-3 clinical trial, which evaluates a new bronchoscopic device designed to relieve trapped air in the lungs and help patients breathe more easily. The Temple Lung Center enrolls hundreds of patients in clinical trials each year, offering access to treatments that are reshaping the future of care.
According to Dr. Criner, "the future of COPD care is about creating treatments that allow patients to live fuller lives." With new therapies and a growing understanding of how environment and gender play a role, there is growing hope for patients with COPD.